Related Experiment Video
Updated: Jun 14, 2026
08:37
Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
Published on: November 5, 2014
LPAR4 mediates resistance to interferon-induced stress in soft tissue sarcoma
Jin-Fen Xiao1, Emily Y Ko1, Ashley Smith1
1Department of Genetics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Science Advances
|June 12, 2026
Summary
The CDK4/6 inhibitor abemaciclib triggers viral mimicry and interferon responses in soft tissue sarcoma. Targeting LPAR4 enhances these effects, offering a new strategy to improve immunotherapy for sarcoma.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Soft tissue sarcomas are aggressive cancers with poor responses to immunotherapy.
- Viral mimicry and type I interferon (IFN-I) signaling can enhance anti-tumor immunity but are understudied in sarcoma.
Purpose of the Study:
- To investigate if CDK4/6 inhibitors can induce viral mimicry and IFN-I responses in sarcoma.
- To identify resistance mechanisms to IFN-I signaling in sarcoma.
- To explore LPAR4 as a therapeutic target to enhance immunotherapy in sarcoma.
Main Methods:
- Treatment of sarcoma cells with abemaciclib.
- Analysis of IFN-I signaling and viral mimicry.
- Genetic silencing of LPAR4.
- Assessment of tumor growth and microenvironment changes in vivo.
Main Results:
- Abemaciclib induced viral mimicry and IFN-I responses in sarcoma cells, suppressing tumor growth and promoting an immune-permissive microenvironment.
- Sarcoma cells developed resistance to IFN-I-induced stress via LPAR4.
- LPAR4 dampened IFN signaling and oxidative stress, promoting cell survival.
- Silencing LPAR4 enhanced IFN responses, increased reactive oxygen species, and sensitized sarcoma cells to apoptosis, delaying tumor growth.
Conclusions:
- Abemaciclib triggers beneficial anti-tumor immune responses in sarcoma by inducing viral mimicry and IFN-I signaling.
- LPAR4 is a key mediator of resistance to IFN-I-driven stress in sarcoma.
- Targeting LPAR4 may enhance the efficacy of viral mimicry-based immunotherapies for soft tissue sarcomas.
Related Concept Videos
01:03Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:03Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...